BR112013028605A2 - vetor viral, vacina recombinante contra prrs e uso de uma vacina - Google Patents

vetor viral, vacina recombinante contra prrs e uso de uma vacina

Info

Publication number
BR112013028605A2
BR112013028605A2 BR112013028605A BR112013028605A BR112013028605A2 BR 112013028605 A2 BR112013028605 A2 BR 112013028605A2 BR 112013028605 A BR112013028605 A BR 112013028605A BR 112013028605 A BR112013028605 A BR 112013028605A BR 112013028605 A2 BR112013028605 A2 BR 112013028605A2
Authority
BR
Brazil
Prior art keywords
vaccine
viral vector
prrs
orf
recombinant prrs
Prior art date
Application number
BR112013028605A
Other languages
English (en)
Inventor
Bernardo Lozano-Dubernard
David Sarfati-Mizrahi
Ernesto Soto-Priante
Jesús Horacio Lara-Puente
Original Assignee
Avi Mex S A De C V Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avi Mex S A De C V Lab filed Critical Avi Mex S A De C V Lab
Publication of BR112013028605A2 publication Critical patent/BR112013028605A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
    • C12N15/8202—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation by biological means, e.g. cell mediated or natural vector
    • C12N15/8203—Virus mediated transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

resumo “vetor viral, vacina recombinante contra prrs e uso de uma vacina” é descrita uma vacina recombinante viva ou inativada, compreendendo um vetor viral e um veículo farmaceuticamente aceitável, adjuvante e/ou excipiente, sendo que o vetor viral é capaz de gerar uma resposta imune celular devido a uma produção de interferon alfa e/ou gama aumentada, e é capaz de uma replicação rápida, e ele tem inserido uma sequência de nucleotídeo da orf 5 e orf 6 a partir de prrs. 1
BR112013028605A 2011-05-07 2011-05-07 vetor viral, vacina recombinante contra prrs e uso de uma vacina BR112013028605A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2011/000977 WO2012153160A1 (es) 2011-05-07 2011-05-07 Vacuna recombinante contra prrs en vector viral

Publications (1)

Publication Number Publication Date
BR112013028605A2 true BR112013028605A2 (pt) 2017-01-17

Family

ID=47138846

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013028605A BR112013028605A2 (pt) 2011-05-07 2011-05-07 vetor viral, vacina recombinante contra prrs e uso de uma vacina

Country Status (10)

Country Link
US (1) US10201602B2 (pt)
EP (1) EP2712927B1 (pt)
JP (1) JP6101251B2 (pt)
KR (1) KR20140033096A (pt)
CN (1) CN103649320A (pt)
BR (1) BR112013028605A2 (pt)
CA (1) CA2834956C (pt)
MX (1) MX351695B (pt)
TW (1) TWI602918B (pt)
WO (1) WO2012153160A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016012406A2 (en) * 2014-07-21 2016-01-28 Istituto Zooprofilattico Sperimentale Della Lombardia E Dell'emilia Romagna "Bruno Ubertini" (Izsler) Attenuated strain of prrs and potential use in immunising preparations

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2289279B (en) 1994-05-13 1998-09-16 Iberica Cyanamid Diagnostic kits and vaccines containing recombinant PRRSV proteins
ATE329616T1 (de) * 1994-08-05 2006-07-15 Univ Minnesota Virale nukleotidsequenz vr-2332 und nutzungsverfahren
FR2751224B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs
US5885513A (en) 1997-03-31 1999-03-23 Northrop Grumman Corporation Resin infusion method
US7192593B2 (en) * 1997-05-23 2007-03-20 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens
US6146642A (en) * 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
SG83740A1 (en) * 1999-08-10 2001-10-16 Inst Of Molecular Agrobiology An attenuated porcine reproductive and respiratory syndrome virus strain and methods of use
EP1255815B1 (en) 2000-02-08 2006-07-19 Regents Of The University Of Minnesota Porcine reproductive and respiratory syndrome virus and methods of use
CN1242065C (zh) 2003-12-26 2006-02-15 南京农业大学 猪繁殖与呼吸综合征重组腺病毒和疫苗
US7722878B2 (en) 2004-06-17 2010-05-25 Boehringer Ingelheim Vetmedica, Inc. PRRSV subunit vaccines
CN100357439C (zh) 2004-11-23 2007-12-26 华中农业大学 一种修饰的猪繁殖与呼吸综合征病毒orf5基因及应用
EP1929047B1 (en) * 2005-08-30 2010-03-17 Board of Regents of the University of Nebraska Methods and compositions for vaccination of animals with prrsv antigens with improved immunogenicity
CN1800375A (zh) 2005-12-23 2006-07-12 南京农业大学 猪繁殖与呼吸综合征与猪圆环病毒重组腺病毒及疫苗
CN101104641B (zh) * 2006-07-11 2012-04-18 生宝生物科技股份有限公司 作为猪生殖和呼吸道征候群疫苗的prrs病毒的融合蛋白
US20100330190A1 (en) * 2007-12-17 2010-12-30 Compans Richard W Immunogenic compositions and methods of use thereof
CN101401937A (zh) * 2008-01-23 2009-04-08 山东省农业科学院畜牧兽医研究所 共表达prrsv orf5及orf6双基因核酸疫苗的制备方法
US8475807B2 (en) * 2008-03-13 2013-07-02 University Of Maryland College Park Avian influenza virus live attenuated vaccine and uses thereof
CN101376027B (zh) * 2008-09-24 2012-06-13 中国农业科学院哈尔滨兽医研究所 表达禽流感病毒H9亚型HA蛋白的重组新城疫病毒LaSota弱毒疫苗株
CN102281896A (zh) * 2008-11-19 2011-12-14 阿维-梅克斯实验室公司 重组失活病毒载体疫苗
CN101880652A (zh) * 2009-07-01 2010-11-10 中国农业科学院哈尔滨兽医研究所 表达猪干扰素(α、β或γ)的重组新城疫弱毒疫苗株
WO2011059334A1 (en) * 2009-11-16 2011-05-19 Stichting Dienst Landbouwkundig Onderzoek Use of newcastle disease virus-based vector for inducing an immune response in mammals
CA2785653C (en) * 2009-12-28 2018-05-01 Merial Limited Recombinant ndv antigen and uses thereof

Also Published As

Publication number Publication date
TW201311899A (zh) 2013-03-16
MX2013012994A (es) 2013-12-12
EP2712927A1 (en) 2014-04-02
CN103649320A (zh) 2014-03-19
US10201602B2 (en) 2019-02-12
EP2712927B1 (en) 2019-08-21
KR20140033096A (ko) 2014-03-17
TWI602918B (zh) 2017-10-21
MX351695B (es) 2017-10-24
WO2012153160A1 (es) 2012-11-15
CA2834956A1 (en) 2012-11-15
CA2834956C (en) 2018-11-20
JP2014515925A (ja) 2014-07-07
US20140199343A1 (en) 2014-07-17
JP6101251B2 (ja) 2017-03-22
EP2712927A4 (en) 2014-11-05

Similar Documents

Publication Publication Date Title
MX2021006931A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
MX2012009581A (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
NZ597182A (en) Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
ES2722799T3 (es) Vacunas contra el cáncer de cerebro basadas en el péptido alfa 2 del receptor de interleuquina-13
DOP2011000268A (es) Vacuna inactivada del virus del dengue con un adjuvante libre de aluminio
PH12016500473A1 (en) Pcv2b divergent vaccine composition and methods of use
PH12019500330A1 (en) Porcine epidemic diarrhea preventative or therapeutic method, vaccine, and vaccine kit
NZ601609A (en) Vaccine vectors and methods of enhancing immune responses
CO2017001614A2 (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9
WO2017192418A8 (en) Therapeutic hpv vaccine combinations
WO2015058772A3 (en) Novel hcv culture systems and direct-acting antiviral sensitivity
NZ739260A (en) Inactivated canine influenza vaccines and methods of making and uses thereof
BR112016010427A2 (pt) proteína para prevenir infecção por mycoplasma spp., composição para prevenir infecção por mycoplasma spp., vetor de expressão, e método para preparar antígeno solúvel
BR112017002440A2 (pt) vírus da diarreia epizoótica porcina mutante para utilização em uma vacina
MX2016001695A (es) Composiciones inmunogenas de combinacion.
BR112013028605A2 (pt) vetor viral, vacina recombinante contra prrs e uso de uma vacina
CL2020002876A1 (es) Vacuna contra la bronquitis infecciosa (divisional de la solicitud no. 201803420)
MY192073A (en) Rhinovaccination system of influenza vaccine
AR110624A1 (es) Vacunas virales
BR112022023096A2 (pt) Vacina recombinante contra covid-19 em um vetor viral de paramixovírus
WO2016012406A3 (en) Attenuated strain of prrs and potential use in immunising preparations
FR3089789B1 (fr) Production de vaccins viraux sur une lignee cellulaire aviaire
AR090472A1 (es) Virus de la enfermedad de marek modificado y vacunas elaboradas con el
NZ756582A (en) Immunogenic compositions against influenza
WO2016141201A3 (en) Rational vaccine design for hepatitis c virus

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL